
Deborah Mulford, M.D.
Contact
About Me
My practice style is patient- and f...
My practice style is patient- and family-focused. I work closely with a multidisciplinary team to determine the best, evidence-based treatment option for each individual. My primary focus is in the treatment of cancers originating from the lung and/or head and neck region. I am a native Rochesterian and am proud to have attended the University of Rochester for medical school.
Conditions I Treat:
- Non small cell lung cancer
- Small cell lung cancer
- Neuroendocrine carcinoma
- Mesothelioma
- Head and neck malignancies
- Thyroid cancer
- Other malignancies
Faculty Appointments
Professor of Clinical Medicine - Department of Medicine, Hematology/Oncology (SMD)
Credentials
Residency & Fellowship
Fellowship, Hematology & Oncology, Memorial Sloan-Kettering Cancer Center. 2002 - 2005
Residency, Internal Medicine, New York University Langone Medical Center-GME. 2000 - 2002
Internship, Internal Medicine, New York University Langone Medical Center-GME. 1999 - 2000
Education
MD | University of Rochester. 1999
Awards
NIH Clinical Loan Repayment Program. 2004 - 2006
Lauri Strauss Leukemia Foundation Endowed Fellowship. 2003 - 2005
Mortimer J. Lacher Fellowship Award. 2003 - 2005
International Cancer Fellowship. 1996 - 1996
U.S. and European Patent-Photographic Apparatus for an Optical Instrument. 1991
Warner King Prize. 1990
Stearns Prize. 1989 - 1990
Eta Kappa Nu and Tau Beta Pi Engineering Honor Societies. 1988 - 1990
Tidmarsh Scholarship for Piano. 1986 - 1990
Research
Clinical Trials
Lead Researcher: Deborah Mulford MD
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin...
Lead Researcher: Deborah Mulford MD
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (re...
Publications
Journal Articles
Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM
Blood advances.. 2023 October 23 Epub 10/23/2023.
Lissa D, Takahashi N, Desai P, Manukyan I, Schultz CW, Rajapakse V, Velez MJ, Mulford D, Roper N, Nichols S, Vilimas R, Sciuto L, Chen Y, Guha U, Rajan A, Atkinson D, El Meskini R, Weaver Ohler Z, Thomas A
Nature communications.. 2022 April 1913 (1):2023. Epub 04/19/2022.
Roper N, Velez MJ, Chiappori A, Kim YS, Wei JS, Sindiri S, Takahashi N, Mulford D, Kumar S, Ylaya K, Trindade C, Manukyan I, Brown AL, Trepel JB, Lee JM, Hewitt S, Khan J, Thomas A
Nature communications.. 2021 June 2312 (1):3880. Epub 06/23/2021.
Komisarof J, Qiu H, Velez MJ, Mulford D
Molecular and clinical oncology.. 2021 April 14 (4):86. Epub 02/26/2021.
Komisarof J, Qiu H, Velez MJ, Mulford D
Molecular and clinical oncology.. 2021 February 14 (2):34. Epub 12/22/2020.
Fernandez KA, Allen P, Campbell M, Page B, Townes T, Li CM, Cheng H, Garrett J, Mulquin M, Clements A, Mulford D, Ortiz C, Brewer C, Dubno JR, Newlands S, Schmitt NC, Cunningham LL
The Journal of clinical investigation.. 2021 January 4131 (1)Epub 1900 01 01.
Milano MT, Bates JE, Budnik J, Qiu H, Hardy S, Cummings MA, Baumgart MA, Maggiore RJ, Mulford DA, Usuki KY
Lung cancer management.. 2020 February 259 (1):LMT25. Epub 02/25/2020.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D,
Lancet.. 2019 October 31 Epub 10/31/2019.
Gajra A, Karim NA, Mulford DA, Villaruz LC, Matrana MR, Ali HY, Santos ES, Berry T, Ong TJ, Sanford A, Amiri K, Spigel DR
Frontiers in oncology.. 2018 8 :253. Epub 07/24/2018.
Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR
British journal of haematology.. 2014 October 167 (2):233-7. Epub 07/18/2014.
Advani AS; McDonough S; Copelan E; Willman C; Mulford DA; List AF; Sekeres MA; Othus M; Appelbaum FR.
British Journal of Hematology. 2014; Volume 167(Issue 2).
Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL
Leukemia research.. 2013 December 37 (12):1622-7. Epub 09/08/2013.
Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA
Journal of hematology & oncology.. 2012 April 305 :18. Epub 04/30/2012.
Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M
Cancer.. 2012 April 15118 (8):2138-47. Epub 09/01/2011.
Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL
Cancer investigation.. 2011 August 29 (7):439-50. Epub 1900 01 01.
Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF
Blood.. 2011 July 21118 (3):523-8. Epub 05/06/2011.
Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG
Clinical cancer research : an official journal of the American Association for Cancer Research.. 2010 November 116 (21):5303-11. Epub 09/21/2010.
Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C
Leukemia research.. 2008 December 32 (12):1830-6. Epub 06/20/2008.
Laughlin TS, Becker MW, Liesveld JL, Mulford DA, Abboud CN, Brown P, Rothberg PG
The Journal of molecular diagnostics : JMD.. 2008 July 10 (4):338-45. Epub 06/13/2008.
Sequential therapy with cytarabine and bismuth-213 (213Bi)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)
Mulford, D.; Pandit-Taskar, N.; McDevitt, M.; Finn, R.; Weiss, M.; Apostolidis, C.; Morgenstern, A.; Divgi, C.; Larson, S.; Scheinberg, D., Jurcic, J.;.
Blood. 2004; .
Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy.
Mulford, D.; Maslak, P.; Weiss, M.; Scheinberg, D.; Jurcic, J.;.
Blood. 2003; : 619a.
Retrospective study to determine if the presence of trisomy 12 by FISH and cytogenetics is predictive of a slowly-progressive chronic lymphocytic leukemia.
Landau, H.; Mulford, D.; Jurcic, J.; Lammanna, N.; Weiss, M.
nab-Paclitaxel-Based Regimens in Underserved Patient Populations Part 2: The ABOUND.PS2 Study in Patients with NSCLC and a Performance Status of 2.
Gajra A; Karim NA; Mulford DA; Villaruz LC; Matrana MR; Haythem YA; Santos ES; Berry T; Ong TJ; Sanford A; Amiri K; Spigel DR.
Frontiers in Oncology, section Thoracic Oncology. .
Books
Cancer Chemotherapy and Biotherapy (2006)
Chapter: Monoclonal Antibody Therapies of Cancer
Authors: Scheinberg DA, Mulford DA, Jurcic JG, Junghans RP, Sgouros G.
Publisher: Baltimore: Lippincott, Williams, And Wilkins 2006